Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LY3962673 |
| Synonyms | |
| Therapy Description |
LY3962673 is a non-covalent KRAS G12D inhibitor that binds to GDP-bound KRAS G12D and decreases MAPK pathway signaling, potentially inhibiting tumor growth (Cancer Res (2024) 84 (6_Supplement): 3316). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LY3962673 | KRAS G12D Inhibitor 25 | LY3962673 is a non-covalent KRAS G12D inhibitor that binds to GDP-bound KRAS G12D and decreases MAPK pathway signaling, potentially inhibiting tumor growth (Cancer Res (2024) 84 (6_Supplement): 3316). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06586515 | Phase I | Leucovorin Nab-paclitaxel Irinotecan Gemcitabine Fluorouracil Oxaliplatin Cetuximab LY3962673 | MOONRAY-01, a Study of LY3962673 in Participants with KRAS G12D-Mutant Solid Tumors (MOONRAY-01) | Recruiting | USA | ITA | IRL | FRA | ESP | DEU | CAN | 2 |